SCHEMBL330457

SCHEMBL330457

SCCC1CCCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL921779 0.97
SCHEMBL23543239 0.92 CYP1A2 (0.42)
SCHEMBL309707 0.90
SCHEMBL18571428 0.89 CYP1A2 (0.41)
SCHEMBL26994 0.83
SCHEMBL330492 0.82 CYP1A2 (0.56)
SCHEMBL12882766 0.82 CYP1A2 (0.56)
SCHEMBL23838569 0.82 CYP1A2 (0.39)
SCHEMBL330126 0.80 SIGMAR1 (0.56)
SCHEMBL8699546 0.80 SIGMAR1 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113748153-B Broadband transparent polysulfide-based copolymers HRL实验室有限责任公司 2023-12-08 CN claimed
CN-114395005-A Modulators of extracellular 5' -nucleotidase and uses thereof 艾库斯生物科学有限公司 2022-04-26 CN claimed
CN-113748153-A Broad band transparent polysulfide-based copolymers HRL实验室有限责任公司 2021-12-03 CN claimed
EP-3761993-A1 PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS Arcus Biosciences, Inc. (US) 2021-01-13 EP claimed
US-20200405629-A1 PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS ARCUS BIOSCIENCES, INC. 2020-12-31 US claimed
CN-112004541-A Immunopotentiating medicine for parenteral administration 艾库斯生物科学有限公司 2020-11-27 CN claimed
US-20190309010-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. 2019-10-10 US claimed
WO-2019173682-A1 PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS ARCUS BIOSCIENCES, INC. (US) 2019-09-12 WO claimed
US-10239912-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ARCUS BIOSCIENCES, INC. (US) 2019-03-26 US claimed
EP-3399984-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF Arcus Biosciences, Inc. (US) 2018-11-14 EP claimed
WO-2018145219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING SERANI MOSTAZAL JORGE (CL) 2018-08-16 WO claimed
US-20170267710-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. 2017-09-21 US claimed
WO-2017120508-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2017-07-13 WO claimed
US-8404731-B2 Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors TRANSTECH PHARMA, INC. (US) 2013-03-26 US claimed
US-7723369-B2 Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors TRANSTECH PHARMA, INC. (US) 2010-05-25 US claimed
US-7504446-B2 Aqueous inks containing colored polymers XEROX CORPORATION (US) 2009-03-17 US claimed
JP-2007505920-A 2007-03-15 JP claimed
EP-1663958-A2 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2006-06-07 EP claimed
US-20060074142-A1 Aqueous inks containing colored polymers XEROX CORPORATION 2006-04-06 US claimed
WO-2005028429-A2 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-03-31 WO claimed